Cytosorbents (CTSO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CTSO Stock Forecast

Cytosorbents stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CTSO Analyst Ratings

Buy

According to 1 Wall Street analysts, Cytosorbents's rating consensus is 'Buy'. The analyst rating breakdown for CTSO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 22, 2024	EF Hutton	Buy	Buy	Hold
Jul 29, 2024	EF Hutton		Buy	Initialise

Cytosorbents's last stock rating was published by EF Hutton on Oct 22, 2024. The company gave CTSO a "Buy" rating, the same as its previous rate.

Cytosorbents Financial Forecast

Cytosorbents Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$8.67M	$8.81M	$9.42M	$7.91M	$7.64M	$6.46M	$7.33M	$7.92M	$9.70M	$8.90M
Avg Forecast	$33.18M	$31.95M	$29.49M	$28.26M	$20.74M	$19.97M	$18.44M	$17.67M	$15.91M	$15.33M	$14.15M	$13.56M	$11.80M	$11.37M	$10.52M	$10.09M	$9.65M	$10.36M	$9.68M	$9.80M	$9.28M	$9.50M	$11.03M	$8.74M	$8.54M	$8.97M	$9.58M	$9.72M	$9.68M	$9.70M
High Forecast	$33.97M	$32.71M	$30.19M	$28.93M	$21.23M	$20.45M	$18.87M	$18.09M	$16.29M	$15.69M	$14.48M	$13.88M	$12.08M	$11.64M	$10.77M	$10.33M	$9.99M	$10.61M	$9.68M	$10.03M	$10.28M	$9.50M	$11.29M	$8.95M	$8.74M	$8.97M	$9.58M	$9.72M	$9.68M	$9.70M
Low Forecast	$32.34M	$31.14M	$28.75M	$27.55M	$20.22M	$19.47M	$17.97M	$17.22M	$15.51M	$14.94M	$13.79M	$13.21M	$11.50M	$11.08M	$10.25M	$9.83M	$9.31M	$10.10M	$9.68M	$9.55M	$7.59M	$9.50M	$10.75M	$8.52M	$8.32M	$8.97M	$9.58M	$9.72M	$9.68M	$9.70M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.93%	0.93%	0.85%	0.90%	0.89%	0.72%	0.77%	0.82%	1.00%	0.92%

Cytosorbents's average Quarter revenue forecast for Mar 24 based on 2 analysts is $9.80M, with a low forecast of $9.55M, and a high forecast of $10.03M. CTSO's average Quarter revenue forecast represents a 13.06% increase compared to the company's last Quarter revenue of $8.67M (Dec 23).

Cytosorbents EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-8.37M	$-7.35M	$-6.56M	$-8.55M	$-10.60M	$-5.51M	$-5.54M	$-6.30M	$-9.43M	$-6.17M
Avg Forecast	$-22.63M	$-21.80M	$-20.12M	$-19.28M	$-14.15M	$-13.62M	$-12.58M	$-12.05M	$-10.86M	$-10.45M	$-9.65M	$-9.25M	$-8.05M	$-7.76M	$-7.17M	$-6.88M	$-6.58M	$-7.07M	$-6.60M	$-6.69M	$-6.33M	$-6.48M	$-7.52M	$-5.96M	$-5.83M	$-6.05M	$-6.46M	$-8.00M	$-6.53M	$-6.55M
High Forecast	$-22.06M	$-21.24M	$-19.61M	$-18.79M	$-13.79M	$-13.28M	$-12.26M	$-11.75M	$-10.58M	$-10.19M	$-9.41M	$-9.01M	$-7.84M	$-7.56M	$-6.99M	$-6.71M	$-6.35M	$-6.89M	$-6.60M	$-6.52M	$-5.18M	$-6.48M	$-7.33M	$-5.81M	$-5.68M	$-6.05M	$-6.46M	$-6.40M	$-6.53M	$-6.55M
Low Forecast	$-23.17M	$-22.31M	$-20.60M	$-19.74M	$-14.48M	$-13.95M	$-12.88M	$-12.34M	$-11.11M	$-10.70M	$-9.88M	$-9.47M	$-8.24M	$-7.94M	$-7.35M	$-7.05M	$-6.81M	$-7.24M	$-6.60M	$-6.84M	$-7.01M	$-6.48M	$-7.70M	$-6.10M	$-5.96M	$-6.05M	$-6.46M	$-9.61M	$-6.53M	$-6.55M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.32%	1.13%	0.87%	1.43%	1.82%	0.91%	0.86%	0.79%	1.44%	0.94%

undefined analysts predict CTSO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cytosorbents's previous annual EBITDA (undefined) of $NaN.

Cytosorbents Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-5.83M	$-9.19M	$-6.15M	$-6.76M	$-766.13K	$-12.15M	$-10.86M	$-8.96M	$-9.31M	$-6.39M
Avg Forecast	$6.51M	$6.27M	$5.79M	$5.56M	$16.34K	$16.34K	$10.89K	$10.89K	$-2.11M	$-2.04M	$-1.88M	$-1.80M	$-2.99M	$-2.99M	$-2.99M	$-3.54M	$-3.54M	$-2.99M	$-5.31M	$-6.53M	$-7.49M	$-6.72M	$-6.16M	$-6.90M	$-9.53M	$-8.96M	$-7.26M	$-8.27M	$-6.81M	$-6.60M
High Forecast	$6.71M	$6.47M	$5.97M	$5.73M	$16.84K	$16.84K	$11.23K	$11.23K	$-2.04M	$-1.97M	$-1.82M	$-1.74M	$-2.90M	$-2.90M	$-2.90M	$-3.42M	$-3.42M	$-2.90M	$-5.13M	$-6.32M	$-4.28M	$-6.49M	$-5.96M	$-6.67M	$-9.22M	$-8.96M	$-7.26M	$-6.62M	$-6.81M	$-6.60M
Low Forecast	$6.29M	$6.07M	$5.60M	$5.38M	$15.80K	$15.80K	$10.53K	$10.53K	$-2.18M	$-2.10M	$-1.94M	$-1.86M	$-3.09M	$-3.09M	$-3.09M	$-3.65M	$-3.65M	$-3.09M	$-5.47M	$-6.74M	$-11.77M	$-6.92M	$-6.35M	$-7.11M	$-9.82M	$-8.96M	$-7.26M	$-9.93M	$-6.81M	$-6.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.78%	1.37%	1.00%	0.98%	0.08%	1.36%	1.49%	1.08%	1.37%	0.97%

Cytosorbents's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CTSO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cytosorbents SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.24M	$8.10M	$7.72M	$9.13M	$8.71M	$9.34M	$9.12M	$9.96M	$11.08M	$8.44M
Avg Forecast	$33.94M	$32.68M	$30.16M	$28.91M	$21.21M	$20.43M	$18.86M	$18.07M	$16.28M	$15.67M	$14.47M	$13.87M	$12.07M	$11.63M	$10.76M	$10.32M	$9.87M	$10.60M	$9.90M	$10.02M	$9.49M	$9.72M	$11.28M	$8.94M	$8.73M	$9.01M	$9.62M	$9.19M	$9.72M	$9.74M
High Forecast	$34.74M	$33.45M	$30.88M	$29.59M	$21.72M	$20.91M	$19.30M	$18.50M	$16.66M	$16.05M	$14.81M	$14.20M	$12.35M	$11.91M	$11.01M	$10.56M	$10.21M	$10.85M	$9.90M	$10.26M	$10.52M	$9.72M	$11.55M	$9.15M	$8.94M	$9.01M	$9.62M	$11.03M	$9.72M	$9.74M
Low Forecast	$33.08M	$31.85M	$29.40M	$28.18M	$20.68M	$19.91M	$18.38M	$17.61M	$15.86M	$15.28M	$14.10M	$13.51M	$11.76M	$11.34M	$10.48M	$10.06M	$9.52M	$10.33M	$9.90M	$9.77M	$7.76M	$9.72M	$10.99M	$8.71M	$8.51M	$9.01M	$9.62M	$7.35M	$9.72M	$9.74M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.97%	0.83%	0.68%	1.02%	1.00%	1.04%	0.95%	1.08%	1.14%	0.87%

Cytosorbents's average Quarter SG&A projection for Mar 24 is $10.02M, based on 2 Wall Street analysts, with a range of $9.77M to $10.26M. The forecast indicates a 8.46% rise compared to CTSO last annual SG&A of $9.24M (Dec 23).

Cytosorbents EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.12	$-0.21	$-0.14	$-0.15	$-0.02	$-0.28	$-0.25	$-0.21	$-0.21	$-0.15
Avg Forecast	$0.12	$0.12	$0.11	$0.10	-	-	-	-	$-0.04	$-0.04	$-0.03	$-0.03	$-0.06	$-0.06	$-0.06	$-0.07	$-0.07	$-0.06	$-0.10	$-0.12	$-0.14	$-0.12	$-0.11	$-0.13	$-0.17	$-0.17	$-0.13	$-0.14	$-0.13	$-0.12
High Forecast	$0.12	$0.12	$0.11	$0.11	-	-	-	-	$-0.04	$-0.04	$-0.03	$-0.03	$-0.05	$-0.05	$-0.05	$-0.06	$-0.06	$-0.05	$-0.09	$-0.12	$-0.08	$-0.12	$-0.11	$-0.12	$-0.17	$-0.17	$-0.13	$-0.14	$-0.13	$-0.12
Low Forecast	$0.12	$0.11	$0.10	$0.10	-	-	-	-	$-0.04	$-0.04	$-0.04	$-0.03	$-0.06	$-0.06	$-0.06	$-0.07	$-0.07	$-0.06	$-0.10	$-0.12	$-0.22	$-0.13	$-0.12	$-0.13	$-0.18	$-0.17	$-0.13	$-0.14	$-0.13	$-0.12
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	1.70%	1.24%	1.18%	0.11%	1.70%	1.87%	1.46%	1.68%	1.23%

According to undefined Wall Street analysts, Cytosorbents's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CTSO previous annual EPS of $NaN (undefined).

Cytosorbents Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CTSO	Cytosorbents	$0.81	$9.00	1011.11%
APYX	Apyx Medical	$1.64	$8.50	418.29%	Buy
TELA	TELA Bio	$2.76	$8.00	189.86%	Buy
INGN	Inogen	$9.12	$26.00	185.09%	Buy
LUNG	Pulmonx	$6.13	$13.00	112.07%	Buy
KIDS	OrthoPediatrics	$22.46	$39.50	75.87%	Buy
LIVN	LivaNova	$49.94	$68.25	36.66%	Buy
OFIX	Orthofix Medical	$17.93	$24.00	33.85%
NPCE	NeuroPace	$11.52	$15.00	30.21%	Buy
FNA	Paragon 28	$10.36	$11.50	11.00%	Buy
CVRX	CVRx	$13.16	$14.25	8.28%	Buy
AORT	Artivion	$28.90	$30.75	6.40%	Buy
SRDX	Surmodics	$39.96	$39.50	-1.15%	Buy
CLPT	ClearPoint Neuro	$16.34	$15.00	-8.20%	Buy

CTSO Forecast FAQ

Is Cytosorbents a good buy?

Yes, according to 1 Wall Street analysts, Cytosorbents (CTSO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CTSO's total ratings.

What are Cytosorbents's analysts' financial forecasts?

Cytosorbents's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $76.82M (high $78.64M, low $74.87M), average EBITDA is $-52.403M (high $-51.076M, low $-53.648M), average net income is $54.45K (high $56.13K, low $52.66K), average SG&A $78.57M (high $80.44M, low $76.58M), and average EPS is $0.001 (high $0.00103, low $0.000967). CTSO's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $122.89M (high $125.8M, low $119.77M), average EBITDA is $-83.829M (high $-81.705M, low $-85.819M), average net income is $24.13M (high $24.88M, low $23.34M), average SG&A $125.69M (high $128.67M, low $122.5M), and average EPS is $0.443 (high $0.457, low $0.429).

Did the CTSO's actual financial results beat the analysts' financial forecasts?

Based on Cytosorbents's last annual report (Dec 2023), the company's revenue was $36.35T, beating the average analysts forecast of $38.55M by 94302882.94%. Apple's EBITDA was $-31.209T, beating the average prediction of $-26.294M by 118691976.33%. The company's net income was $-28.507T, beating the average estimation of $-27.264M by 104562273.25%. Apple's SG&A was $33.6T, beating the average forecast of $39.42M by 85228407.71%. Lastly, the company's EPS was $-0.64, beating the average prediction of $-0.501 by 27.83%. In terms of the last quarterly report (Dec 2023), Cytosorbents's revenue was $8.67M, missing the average analysts' forecast of $9.28M by -6.54%. The company's EBITDA was $-8.369M, beating the average prediction of $-6.327M by 32.27%. Cytosorbents's net income was $-5.835M, missing the average estimation of $-7.487M by -22.07%. The company's SG&A was $9.24M, missing the average forecast of $9.49M by -2.58%. Lastly, the company's EPS was $-0.12, missing the average prediction of $-0.138 by -12.73%